For instance, the presence of exosomal EGFR mutations in patients with non-small cell lung cancer can provide a crucial basis for the utilization of specific EGFR inhibitors, thereby enabling highly personalized and effective treatment strategies [30]. Here, EGFR is linked to non-small cell lung carcinoma.